Sign in

You're signed outSign in or to get full access.

Peyton Balthrop

Research Analyst at TD Cowen

Peyton Balthrop's questions to ARDELYX (ARDX) leadership

Question · Q4 2025

Peyton Balthrop asked about the powering of the CIC trial and the target proportion of CSBM responders.

Answer

Chief Patient Officer and Interim Chief Medical Officer Laura Williams stated the trial is robustly powered at 95% with approximately 700 patients (173 per arm). She added that the target is an 18-20% difference in CSBM responder rate between placebo and active drug, based on data from the TEMPO studies.

Ask follow-up questions

Fintool

Fintool can predict ARDELYX logo ARDX's earnings beat/miss a week before the call